最新一期业绩显示，2025年一季报，公司实现营业收入9741.58万元，同比8.68%；净利润2662.67万 元，同比-34.06%，销售毛利率80.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)68正海生物31.0227.854.1037.49亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2澳华内 镜-726.69364.475.8276.58亿3诺唯赞-431.93-510.862.3792.43亿4爱朋医疗-431.66327.945.2035.42亿5博晖 创新-337.40535.413.6049.50亿6硕世生物-147.79-2159.571.3243.23亿7奥精医疗-142.33-208.621.8826.42亿 8睿昂基因-105.65-86.741.5013.67亿9康泰医学-87.85-74.223.1357.82亿10中红医疗-74.13-59.130.9451.52亿 11热景生物-67.89-78.225.01149.40亿 来源：金融界 6月 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Zhenghai Biological, noting its stock price increase and market capitalization [1] - As of May 29, Zhenghai Biological's closing price was 19.95 yuan, with a rolling PE ratio of 29.71 times and a total market value of 3.591 billion yuan [1] - The company ranks 67th in the medical device industry, which has an average PE ratio of 49.64 times and a median of 36.36 times [1] Group 2 - Zhenghai Biological's main business involves the research, production, and sales of bio-regenerative materials, including oral repair membranes and absorbable dura mater patches [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] - In the first quarter of 2025, the company reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, while net profit was 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which closed at 20.38 yuan, with a PE ratio of 30.35, marking a new low in 23 days, and a total market capitalization of 3.668 billion yuan [1] - Zhenghai Biological ranks 67th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1] - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Zhenghai Biological involves the research, production, and sales of bio-regenerative materials, including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, as announced by the Shandong Provincial Department of Industry and Information Technology [1] - In the latest quarterly report for Q1 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

再生医学（regenerative medicine，RM），是指利用生命科学、工程学、计算机科学等多学科的理论和 方法，融合材料科学、细胞技术、组织工程技术、基因工程技术等多项现代生物工程技术，促进机体自 我修复与再生，或构建新的组织与器官，实现修复、替代和增强人体内受损、病变或有缺陷的组织和器 官的医学技术。 内容概要：再生医学（regenerative medicine，RM）是指利用生物学及工程学的理论方法，促进机体自 我修复与再生，或构建新的组织与器官，以修复、再生和替代受损的组织和器官的医学技术。近年来， 随着全球人口老龄化趋势的加快和慢性病、癌症等疾病的发病率上升，对先进医疗技术的需求不断增 长。而再生医学作为一种创新疗法，为这些疾病提供了新的治疗途径。因此，当前全球再生医学市场规 模正在持续扩张。数据显示，2024年全球再生医学市场规模已从2021年的200.4亿美元增长至358.2亿美 元。 相关上市企业：佰仁医疗（688198）；冠昊生物（300238）；正海生物（300653）；迈普医学 （301033）等 相关企业：诺一迈尔（苏州）医学科技有限公司；深圳华源再生医学公司；京东方再生医学 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年3月26日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第3号），有 14款产品 进入创新通道。其中包括， 卓阮医疗科技（苏州）有限公 司 申请的" 生物疝修补补片 "。 # 揭开"基底膜"的神秘面纱 # 生物疝修补补片 材料来源 ：该产品由猪膀胱基底膜和猪小肠粘膜下层经过脱细胞处理、复合制成的 三明治结构补片 。 在机体的自我修复过程中，完整的BM对子宫内膜、皮肤、肌肉、角膜等组织功能性再生必不可少。如同机体内的天然BM的惊人诱导再生能力，BM产品植入后可 以快速促进机体细胞的黏附、迁移和分化，帮助组织特异性细胞定位并引导组织有序性再生，显著增强组织修复和伤口愈合，实现组织特异性再生。 超高生物活性 调节机体免疫应答，组织相容性高 降低瘢痕、降低粘连组织形成 减少并发症、远期力学强度稳定 有助于实现部分程度的特异性、功能性修复 结构特点 ：产品设计为" 粘膜下层+基底膜" 的仿生结构，具有贯穿孔，加速周围组织细胞长入，利于组 ...